First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

被引：0
|
作者：
Chan, S. [1 ]
Chiang, C. [1 ]
Lee, S. [2 ]
Choi, H. [1 ]
机构：
[1] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [1] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    [J]. CANCERS, 2021, 13 (05) : 1 - 13
  • [2] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
    Hou, Yanli
    Wu, Bin
    [J]. CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745
  • [3] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    [J]. JAMA NETWORK OPEN, 2021, 4 (02)
  • [4] Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
    Chee, Cheng Ean
    Khara, Jasmeet Singh
    Cheong, John
    Fong, Jek
    Sivanesan, Sivabalan
    Choy, Jian Yi
    Hu, Meibo
    Viswambaram, Amrita
    Toh, Han Chong
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 631 - 641
  • [5] Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
    Tseng, Chien-Yu
    Tsai, Yi-Wen
    Shiu, Ming-Neng
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    [J]. CANCER, 2022, 128 (22) : 3995 - 4003
  • [7] Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [9] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
12345